Gameto Raises $44M to Fund US Trial for Egg-Freezing Therapy

Gameto Inc., a biotech company, has raised $44 million in venture capital to fund a clinical trial for its egg-freezing therapy, Fertilo. The technique uses stem cells engineered into ovarian support cells to improve the egg-freezing experience, reducing the need for grueling injections. Early data shows the procedure is effective and could become a multibillion-dollar revenue opportunity. The treatment is already available in Mexico, Peru, and Australia, with plans to expand to more countries.

Biotech company Gameto Inc. has secured $44 million in venture capital funding to support its clinical trial for the Fertilo egg-freezing therapy. The funding round, led by Overwater Ventures, will facilitate the development of the technique, which aims to enhance the egg-freezing process by using stem cells engineered into ovarian support cells [1].

The Fertilo therapy aims to reduce the need for the grueling two weeks of injections typically required during fertility treatment. Instead, patients are administered three days of injections, followed by egg extraction and maturation by the engineered cells. This innovative approach could significantly improve the patient experience and potentially reduce the side effects associated with traditional egg-freezing methods [1].

Early data from the company suggests that the Fertilo technique is effective and could open up a multibillion-dollar market opportunity over time. The treatment is currently available in Mexico, Peru, and Australia, with plans to expand its reach to more countries. The company has also expressed interest in exploring other applications for its engineered support cells, such as treating symptoms of menopause and maintaining ovarian health [1].

Gameto Inc. was founded in 2020 and has raised a total of $127 million in funding, including contributions from Insight Partners, RA Capital, and Two Sigma Ventures. The company's co-founder, Martin Varsavsky, is also the founder of the Prelude Fertility clinic chain in North America [1].

Kristina Simmons, who led Gameto's latest funding round at Overwater Ventures, expects the company to dramatically expand opportunities for women who want to freeze their eggs or live longer without the effects of menopause. As human fertility is increasingly affected by man-made chemicals and pesticides, the need for therapies like Gameto's is expected to grow. The company has the potential to drive significant transformation in women's health [1].

References:
[1] https://www.bloomberg.com/news/articles/2025-08-12/fertility-startup-gameto-raises-44-million-to-test-egg-freezing-therapy-in-us